

Resource Summary Report

Generated by [dkNET](#) on Sep 21, 2026

SUM159PT

RRID:CVCL_5423

Type: Cell Line

Proper Citation

RRID:CVCL_5423

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5423

Proper Citation: RRID:CVCL_5423

Description: Cell line SUM159PT is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast pleomorphic carcinoma

Defining Citation: [PMID:10424408](#), [PMID:10604729](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19593635](#), [PMID:21778573](#), [PMID:23151021](#), [PMID:23401782](#), [PMID:23601657](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26735014](#), [PMID:28889351](#), [PMID:32416067](#), [PMID:32715085](#), [PMID:34320349](#), [PMID:35042871](#)

Comments: Part of: JWGray breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUM159PT

Synonyms: SUM-159-PT, SUM-159PT, SUM 159PT, SUM-159, SUM 159, SUM159, 159 PT, 159PT

Cross References: BTO:BTO_0004928, CLO:CLO_0009918, EFO:EFO_0001241, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-11134, ArrayExpress:E-TABM-157, BioGRID_ORCS_Cell_line:1394, BioSample:SAMN03472960,

cancercelllines:CVCL_5423, Cell_Model_Passport:SIDM01452, ChEMBL-Cells:ChEMBL4483124, ChEMBL-Targets:ChEMBL4483269, CLS:305116, Cosmic:904389, Cosmic:1046944, Cosmic:1136380, Cosmic:1287924, Cosmic:1289412, Cosmic:1460240, DepMap:ACH-001391, EGA:EGAS00001000610, GEO:GSM75170, GEO:GSM217601, GEO:GSM412074, GEO:GSM412089, GEO:GSM412092, GEO:GSM412105, GEO:GSM412114, GEO:GSM412117, GEO:GSM421890, GEO:GSM474278, GEO:GSM474279, GEO:GSM476481, GEO:GSM476482, GEO:GSM476483, GEO:GSM478318, GEO:GSM478319, GEO:GSM478323, GEO:GSM478324, GEO:GSM844706, GEO:GSM844707, GEO:GSM847434, GEO:GSM847501, GEO:GSM967817, GEO:GSM967822, GEO:GSM1008917, GEO:GSM1053735, GEO:GSM1172993, GEO:GSM1214567, GEO:GSM1401652, GEO:GSM3145737, IARC_TP53:24342, LINCS_HMS:51083, LINCS_LDP:LCL-2068, PharmacDB:SUM159PT_1510_2019, Progenetix:CVCL_5423, PubChem_Cell_line:CVCL_5423, SLKBase:256, Wikidata:Q54970841

ID: CVCL_5423

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260920T005904+0000

Ratings and Alerts

No rating or validation information has been found for SUM159PT.

No alerts have been found for SUM159PT.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 414 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Luo Y, et al. (2026) piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer. *Molecular cancer*, 25(1).

Christenson JL, et al. (2026) Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic Outgrowth. *Cancer research communications*, 6(4), 750.

He L, et al. (2026) Repurposing Quetiapine as an Adjuvant Therapeutic Agent for Triple-Negative Breast Cancer. *Radiation research*, 206(1), 55.

Chen F, et al. (2026) Three-Dimensional Tumor Spheroids Reveal B7-H3 CAR T Cell Infiltration Dynamics and Microenvironment-Induced Functional Reprogramming in Solid

Tumors. Cells, 15(2).

Spartz A, et al. (2026) Modeling the role of urokinase-type plasminogen activator, uPA, and circulating cancer-associated fibroblasts (cCAFs) in breast cancer cell extravasation. Clinical & experimental metastasis, 43(3).

Yang T, et al. (2026) Targeting the USP7-PRMT6 epigenetic axis overcomes chemoresistance in breast cancer by coordinating H3R2me2a deposition and RNF168 methylation for DNA repair and ferroptosis blockade. Cell death and differentiation, 33(8), 1598.

Holmes JC, et al. (2026) Ligand Electronics Dictate Geometry, Stability, and Cancer Cell Toxicity in Carbon-Stabilized Gold(III) Macrocycles. Chembiochem : a European journal of chemical biology, 27(7), e202500962.

David T, et al. (2025) Cathepsins: Novel opportunities for antibody therapeutics in cancer. British journal of pharmacology, 182(8), 1671.

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. Cell reports. Medicine, 6(8), 102252.

Shan M, et al. (2025) PCDHGB7 inhibits the progression of triple-negative breast cancer by suppressing XRCC5/MYC-mediated ribosome biogenesis. Clinical and translational medicine, 15(9), e70437.

Souto EP, et al. (2025) Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor-Initiating Cells Characterized by IFN/STAT1 Activity. Cancer research, 85(8), 1390.

Mahajan M, et al. (2025) The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. Molecular cancer therapeutics, 24(9), 1308.

Wang Z, et al. (2025) Oncogenic HNF4?? inhibits ferroptotic cell death through activating SLC7A11 by recruiting p300/CBP in breast cancer. Biochimica et biophysica acta. Molecular basis of disease, 1871(6), 167884.

Roichman A, et al. (2025) Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors. Cell, 188(11), 3065.

Neill NJ, et al. (2025) Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer discovery, 15(11), 2326.

Gonzalez-Lozano MA, et al. (2025) EndoMAP.v1 charts the structural landscape of human early endosome complexes. Nature, 643(8070), 252.

Liu Y, et al. (2025) Mechanism by which the molecular glue-like verteporfin induces IRE1?? dimerization and activation to synergize with AKT inhibition in breast cancer. Cell chemical biology, 32(6), 854.

Sun Y, et al. (2025) TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids. *Cancer immunology research*, 13(2), 210.

Renzi G, et al. (2025) Dual inhibition of carbonic anhydrase IX and glutathione peroxidase 4 as a novel strategy for ferroptosis-induced tumor cell death. *European journal of medicinal chemistry*, 300, 118107.

Piemonte KM, et al. (2024) Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer. *Cancer research*, 84(21), 3556.